Expertise in
46
conditions

Dr. Makenzi C. Evangelist

Hematology | Oncology
Albany Medical Center
43 New Scotland Ave, 
Albany, NY 
Offers Telehealth
Expertise in
46
conditions
Albany Medical Center
43 New Scotland Ave, 
Albany, NY 

Overview

Makenzi Evangelist is a Hematologist and an Oncologist practicing medicine in Albany, New York.

Dr. Evangelist is highly rated in 46 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Non-Small Cell Lung Cancer (NSCLC).

She is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

Columbia Memorial Hospital
Samaritan Hospital Of Troy, New York
Albany Medical Center Hospital
St Peter's Hospital
Ellis Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Albany Medical Center
43 New Scotland Ave, Albany, NY 12208

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

7 Total Publications

Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices.
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices.
Journal: JCO precision oncology
Published: April 22, 2026
Similar Doctors
Expertise in
29
conditions
Dr. Rahul Ravilla
Hematology | Oncology
Expertise in
29
conditions
Dr. Rahul Ravilla
Hematology | Oncology
Referral may be required

St. Peter's Health Partners Medical Associates P.C.

400 Patroon Creek Blvd, 
Albany, NY 
 (2.5 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rahul Ravilla is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Ravilla is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Upper Tract Urothelial Carcinoma (UTUC), Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

Expertise in
26
conditions
Dr. Ira L. Zackon
Hematology | Oncology
Expertise in
26
conditions
Dr. Ira L. Zackon
Hematology | Oncology
Referral may be required

Albany Medical Center

43 New Scotland Ave, 
Albany, NY 
 (0.1 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances

Ira Zackon is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Zackon is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Plasmacytoma, and Bone Marrow Aspiration.

Expertise in
62
conditions
Dr. Charlene A. Ives
Hematology | Oncology
Expertise in
62
conditions
Dr. Charlene A. Ives
Hematology | Oncology
Referral may be required

New York Oncology Hematology PC

258 Hoosick St, Ste 206, 
Troy, NY 
 (7.9 miles away)
518-272-2097
Languages Spoken:
English
See accepted insurances

Charlene Ives is a Hematologist and an Oncologist practicing medicine in Troy, New York. Dr. Ives is highly rated in 62 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Paget Disease of the Breast, Breast Cancer, and Colorectal Cancer. Dr. Ives is board certified in American Board Of Internal Medicine Subspecialty, Medical Oncology.

Frequently Asked Questions about Dr. Makenzi C. Evangelist

How do I make an appointment with Dr. Makenzi C. Evangelist?

You can book an appointment with Dr. Makenzi C. Evangelist by calling their office at 518-262-6696. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Makenzi C. Evangelist a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Makenzi C. Evangelist is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Makenzi C. Evangelist specialize in?

While Dr. Makenzi C. Evangelist is a Hematology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Makenzi C. Evangelist participate in research or clinical trials?

Yes. Dr. Makenzi C. Evangelist has published 7 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Makenzi C. Evangelist's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Makenzi C. Evangelist accept my insurance?

Dr. Makenzi C. Evangelist accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 518-262-6696 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Evangelist's expertise for a condition
ConditionClose
    View All 42 Advanced Conditions
    View All 144 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile